Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide

B-cell lymphoma frequently shows simultaneous dissemination to multiple organs. It also occasionally involves bone and causes osteolytic lesions. To study the mechanisms responsible for this capacity of lymphoma cells to grow in different tissue microenvironments and search for effective therapeutic...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical & experimental metastasis 1998-10, Vol.16 (7), p.645-654
Hauptverfasser: Michigami, T, Nomizu, M, Yamada, Y, Dunstan, C, Williams, P J, Munday, G R, Yoneda, T
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 654
container_issue 7
container_start_page 645
container_title Clinical & experimental metastasis
container_volume 16
creator Michigami, T
Nomizu, M
Yamada, Y
Dunstan, C
Williams, P J
Munday, G R
Yoneda, T
description B-cell lymphoma frequently shows simultaneous dissemination to multiple organs. It also occasionally involves bone and causes osteolytic lesions. To study the mechanisms responsible for this capacity of lymphoma cells to grow in different tissue microenvironments and search for effective therapeutic interventions for this hematological malignancy, we established a new murine B-cell lymphoma cell line named MH-95. The tumor disseminated to multiple organs including the lung, liver, kidney, spleen and lymph nodes within 2 weeks after subcutaneous inoculation in nude mice. In addition, the tumor also grew in bone and caused osteoclastic osteolytic lesions. Thus, this tumor model mimics the behavior in many ways of B-cell lymphoma in humans. We studied the role of laminin, a major component of the basement membrane, in this model, since although it has been implicated in solid tumor metastasis, little is known about the involvement of laminin in the growth of B-cell lymphoma in bone and other organs. Immunohistochemical examination showed strong laminin expression in the stroma of the primary subcutaneous tumor and tumors in the bone and other organs. Systemic administration of the antagonistic laminin peptide YIGSR decreased primary tumor growth and tumor cell deposit in the bone, liver and kidney. In addition, the peptide also decreased apparent neovascularization in the tumor, suggesting that the peptide suppressed angiogenesis presumably due to inhibition of laminin binding to its receptors. These results demonstrate that the MH-95 B-cell lymphoma cells express laminin and suggest that laminin plays a critical role in the growth and simultaneous dissemination of tumor cells to multiple organs, similar to what has been described in solid tumors. The results also suggest that suppression of angiogenesis through interfering with laminin actions may be a useful adjuvant therapy for B-cell lymphoma.
doi_str_mv 10.1023/a:1006502528268
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_69156673</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69156673</sourcerecordid><originalsourceid>FETCH-LOGICAL-c387t-482bd6941663d9fc3f5f1005b7683c5ede57271d606f6201e2adf3db772ef0113</originalsourceid><addsrcrecordid>eNpVkL1PwzAQxT2ASinMTEie2EL90dgOW6mgVKqExMfAFDnxWTGKk2CnqvLfk6oVEtPpdL_3dO8hdEPJPSWMz_UDJUSkhKVMMaHO0JQwwRKiMnWBLmP8JoQspFQTNMkyzgSlUzSsQ7vvK6wbg42LEbxrdO_aBrcWa9zAvh4SiL0uahcrMNjvgmsAPyYl1DWuB99Vrdf4uB0uLmLXVK5w_UgXwyioe-chuBJ_bdbvb7iDrncGrtC51XWE69Ococ_np4_VS7J9XW9Wy21SciX7ZKFYYUS2oEJwk9mS29SOMdNCCsXLFAykkklqBBFWMEKBaWO5KaRkYAmlfIbujr5daH92Y5Tcu3h4VzfQ7mIuMpoKIfkIzo9gGdoYA9i8C87rMOSU5IeC82X-r-BRcXuy3hUezB9_apf_AkpIeMM</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>69156673</pqid></control><display><type>article</type><title>Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Michigami, T ; Nomizu, M ; Yamada, Y ; Dunstan, C ; Williams, P J ; Munday, G R ; Yoneda, T</creator><creatorcontrib>Michigami, T ; Nomizu, M ; Yamada, Y ; Dunstan, C ; Williams, P J ; Munday, G R ; Yoneda, T</creatorcontrib><description>B-cell lymphoma frequently shows simultaneous dissemination to multiple organs. It also occasionally involves bone and causes osteolytic lesions. To study the mechanisms responsible for this capacity of lymphoma cells to grow in different tissue microenvironments and search for effective therapeutic interventions for this hematological malignancy, we established a new murine B-cell lymphoma cell line named MH-95. The tumor disseminated to multiple organs including the lung, liver, kidney, spleen and lymph nodes within 2 weeks after subcutaneous inoculation in nude mice. In addition, the tumor also grew in bone and caused osteoclastic osteolytic lesions. Thus, this tumor model mimics the behavior in many ways of B-cell lymphoma in humans. We studied the role of laminin, a major component of the basement membrane, in this model, since although it has been implicated in solid tumor metastasis, little is known about the involvement of laminin in the growth of B-cell lymphoma in bone and other organs. Immunohistochemical examination showed strong laminin expression in the stroma of the primary subcutaneous tumor and tumors in the bone and other organs. Systemic administration of the antagonistic laminin peptide YIGSR decreased primary tumor growth and tumor cell deposit in the bone, liver and kidney. In addition, the peptide also decreased apparent neovascularization in the tumor, suggesting that the peptide suppressed angiogenesis presumably due to inhibition of laminin binding to its receptors. These results demonstrate that the MH-95 B-cell lymphoma cells express laminin and suggest that laminin plays a critical role in the growth and simultaneous dissemination of tumor cells to multiple organs, similar to what has been described in solid tumors. The results also suggest that suppression of angiogenesis through interfering with laminin actions may be a useful adjuvant therapy for B-cell lymphoma.</description><identifier>ISSN: 0262-0898</identifier><identifier>DOI: 10.1023/a:1006502528268</identifier><identifier>PMID: 9932611</identifier><language>eng</language><publisher>Netherlands</publisher><subject>Amino Acids, Diamino - antagonists &amp; inhibitors ; Animals ; Antineoplastic Agents - therapeutic use ; Cell Division - drug effects ; Cell Movement - drug effects ; Endothelium, Vascular - pathology ; Humans ; Immunohistochemistry ; Lymphoma, B-Cell - drug therapy ; Lymphoma, B-Cell - pathology ; Mice ; Mice, Nude ; Neoplasm Metastasis ; Neovascularization, Pathologic ; Oligopeptides - therapeutic use ; Reverse Transcriptase Polymerase Chain Reaction ; Tumor Cells, Cultured ; Umbilical Veins</subject><ispartof>Clinical &amp; experimental metastasis, 1998-10, Vol.16 (7), p.645-654</ispartof><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c387t-482bd6941663d9fc3f5f1005b7683c5ede57271d606f6201e2adf3db772ef0113</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,778,782,27911,27912</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9932611$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Michigami, T</creatorcontrib><creatorcontrib>Nomizu, M</creatorcontrib><creatorcontrib>Yamada, Y</creatorcontrib><creatorcontrib>Dunstan, C</creatorcontrib><creatorcontrib>Williams, P J</creatorcontrib><creatorcontrib>Munday, G R</creatorcontrib><creatorcontrib>Yoneda, T</creatorcontrib><title>Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide</title><title>Clinical &amp; experimental metastasis</title><addtitle>Clin Exp Metastasis</addtitle><description>B-cell lymphoma frequently shows simultaneous dissemination to multiple organs. It also occasionally involves bone and causes osteolytic lesions. To study the mechanisms responsible for this capacity of lymphoma cells to grow in different tissue microenvironments and search for effective therapeutic interventions for this hematological malignancy, we established a new murine B-cell lymphoma cell line named MH-95. The tumor disseminated to multiple organs including the lung, liver, kidney, spleen and lymph nodes within 2 weeks after subcutaneous inoculation in nude mice. In addition, the tumor also grew in bone and caused osteoclastic osteolytic lesions. Thus, this tumor model mimics the behavior in many ways of B-cell lymphoma in humans. We studied the role of laminin, a major component of the basement membrane, in this model, since although it has been implicated in solid tumor metastasis, little is known about the involvement of laminin in the growth of B-cell lymphoma in bone and other organs. Immunohistochemical examination showed strong laminin expression in the stroma of the primary subcutaneous tumor and tumors in the bone and other organs. Systemic administration of the antagonistic laminin peptide YIGSR decreased primary tumor growth and tumor cell deposit in the bone, liver and kidney. In addition, the peptide also decreased apparent neovascularization in the tumor, suggesting that the peptide suppressed angiogenesis presumably due to inhibition of laminin binding to its receptors. These results demonstrate that the MH-95 B-cell lymphoma cells express laminin and suggest that laminin plays a critical role in the growth and simultaneous dissemination of tumor cells to multiple organs, similar to what has been described in solid tumors. The results also suggest that suppression of angiogenesis through interfering with laminin actions may be a useful adjuvant therapy for B-cell lymphoma.</description><subject>Amino Acids, Diamino - antagonists &amp; inhibitors</subject><subject>Animals</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Cell Division - drug effects</subject><subject>Cell Movement - drug effects</subject><subject>Endothelium, Vascular - pathology</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Lymphoma, B-Cell - drug therapy</subject><subject>Lymphoma, B-Cell - pathology</subject><subject>Mice</subject><subject>Mice, Nude</subject><subject>Neoplasm Metastasis</subject><subject>Neovascularization, Pathologic</subject><subject>Oligopeptides - therapeutic use</subject><subject>Reverse Transcriptase Polymerase Chain Reaction</subject><subject>Tumor Cells, Cultured</subject><subject>Umbilical Veins</subject><issn>0262-0898</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1998</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNpVkL1PwzAQxT2ASinMTEie2EL90dgOW6mgVKqExMfAFDnxWTGKk2CnqvLfk6oVEtPpdL_3dO8hdEPJPSWMz_UDJUSkhKVMMaHO0JQwwRKiMnWBLmP8JoQspFQTNMkyzgSlUzSsQ7vvK6wbg42LEbxrdO_aBrcWa9zAvh4SiL0uahcrMNjvgmsAPyYl1DWuB99Vrdf4uB0uLmLXVK5w_UgXwyioe-chuBJ_bdbvb7iDrncGrtC51XWE69Ococ_np4_VS7J9XW9Wy21SciX7ZKFYYUS2oEJwk9mS29SOMdNCCsXLFAykkklqBBFWMEKBaWO5KaRkYAmlfIbujr5daH92Y5Tcu3h4VzfQ7mIuMpoKIfkIzo9gGdoYA9i8C87rMOSU5IeC82X-r-BRcXuy3hUezB9_apf_AkpIeMM</recordid><startdate>19981001</startdate><enddate>19981001</enddate><creator>Michigami, T</creator><creator>Nomizu, M</creator><creator>Yamada, Y</creator><creator>Dunstan, C</creator><creator>Williams, P J</creator><creator>Munday, G R</creator><creator>Yoneda, T</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>19981001</creationdate><title>Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide</title><author>Michigami, T ; Nomizu, M ; Yamada, Y ; Dunstan, C ; Williams, P J ; Munday, G R ; Yoneda, T</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c387t-482bd6941663d9fc3f5f1005b7683c5ede57271d606f6201e2adf3db772ef0113</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1998</creationdate><topic>Amino Acids, Diamino - antagonists &amp; inhibitors</topic><topic>Animals</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Cell Division - drug effects</topic><topic>Cell Movement - drug effects</topic><topic>Endothelium, Vascular - pathology</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Lymphoma, B-Cell - drug therapy</topic><topic>Lymphoma, B-Cell - pathology</topic><topic>Mice</topic><topic>Mice, Nude</topic><topic>Neoplasm Metastasis</topic><topic>Neovascularization, Pathologic</topic><topic>Oligopeptides - therapeutic use</topic><topic>Reverse Transcriptase Polymerase Chain Reaction</topic><topic>Tumor Cells, Cultured</topic><topic>Umbilical Veins</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Michigami, T</creatorcontrib><creatorcontrib>Nomizu, M</creatorcontrib><creatorcontrib>Yamada, Y</creatorcontrib><creatorcontrib>Dunstan, C</creatorcontrib><creatorcontrib>Williams, P J</creatorcontrib><creatorcontrib>Munday, G R</creatorcontrib><creatorcontrib>Yoneda, T</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical &amp; experimental metastasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Michigami, T</au><au>Nomizu, M</au><au>Yamada, Y</au><au>Dunstan, C</au><au>Williams, P J</au><au>Munday, G R</au><au>Yoneda, T</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide</atitle><jtitle>Clinical &amp; experimental metastasis</jtitle><addtitle>Clin Exp Metastasis</addtitle><date>1998-10-01</date><risdate>1998</risdate><volume>16</volume><issue>7</issue><spage>645</spage><epage>654</epage><pages>645-654</pages><issn>0262-0898</issn><abstract>B-cell lymphoma frequently shows simultaneous dissemination to multiple organs. It also occasionally involves bone and causes osteolytic lesions. To study the mechanisms responsible for this capacity of lymphoma cells to grow in different tissue microenvironments and search for effective therapeutic interventions for this hematological malignancy, we established a new murine B-cell lymphoma cell line named MH-95. The tumor disseminated to multiple organs including the lung, liver, kidney, spleen and lymph nodes within 2 weeks after subcutaneous inoculation in nude mice. In addition, the tumor also grew in bone and caused osteoclastic osteolytic lesions. Thus, this tumor model mimics the behavior in many ways of B-cell lymphoma in humans. We studied the role of laminin, a major component of the basement membrane, in this model, since although it has been implicated in solid tumor metastasis, little is known about the involvement of laminin in the growth of B-cell lymphoma in bone and other organs. Immunohistochemical examination showed strong laminin expression in the stroma of the primary subcutaneous tumor and tumors in the bone and other organs. Systemic administration of the antagonistic laminin peptide YIGSR decreased primary tumor growth and tumor cell deposit in the bone, liver and kidney. In addition, the peptide also decreased apparent neovascularization in the tumor, suggesting that the peptide suppressed angiogenesis presumably due to inhibition of laminin binding to its receptors. These results demonstrate that the MH-95 B-cell lymphoma cells express laminin and suggest that laminin plays a critical role in the growth and simultaneous dissemination of tumor cells to multiple organs, similar to what has been described in solid tumors. The results also suggest that suppression of angiogenesis through interfering with laminin actions may be a useful adjuvant therapy for B-cell lymphoma.</abstract><cop>Netherlands</cop><pmid>9932611</pmid><doi>10.1023/a:1006502528268</doi><tpages>10</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0262-0898
ispartof Clinical & experimental metastasis, 1998-10, Vol.16 (7), p.645-654
issn 0262-0898
language eng
recordid cdi_proquest_miscellaneous_69156673
source MEDLINE; Springer Nature - Complete Springer Journals
subjects Amino Acids, Diamino - antagonists & inhibitors
Animals
Antineoplastic Agents - therapeutic use
Cell Division - drug effects
Cell Movement - drug effects
Endothelium, Vascular - pathology
Humans
Immunohistochemistry
Lymphoma, B-Cell - drug therapy
Lymphoma, B-Cell - pathology
Mice
Mice, Nude
Neoplasm Metastasis
Neovascularization, Pathologic
Oligopeptides - therapeutic use
Reverse Transcriptase Polymerase Chain Reaction
Tumor Cells, Cultured
Umbilical Veins
title Growth and dissemination of a newly-established murine B-cell lymphoma cell line is inhibited by multimeric YIGSR peptide
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-16T03%3A01%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Growth%20and%20dissemination%20of%20a%20newly-established%20murine%20B-cell%20lymphoma%20cell%20line%20is%20inhibited%20by%20multimeric%20YIGSR%20peptide&rft.jtitle=Clinical%20&%20experimental%20metastasis&rft.au=Michigami,%20T&rft.date=1998-10-01&rft.volume=16&rft.issue=7&rft.spage=645&rft.epage=654&rft.pages=645-654&rft.issn=0262-0898&rft_id=info:doi/10.1023/a:1006502528268&rft_dat=%3Cproquest_cross%3E69156673%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=69156673&rft_id=info:pmid/9932611&rfr_iscdi=true